Bio-View Ltd - Asset Resilience Ratio
Bio-View Ltd (BIOV) has an Asset Resilience Ratio of 7.61% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BIOV current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2023–2024)
This chart shows how Bio-View Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Bio-View Ltd total assets.
Liquid Assets Composition Over Time
This chart breaks down Bio-View Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read BIOV total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ILA0.00 | 0% |
| Short-term Investments | ILA2.15 Million | 7.61% |
| Total Liquid Assets | ILA2.15 Million | 7.61% |
Asset Resilience Insights
- Limited Liquidity: Bio-View Ltd maintains only 7.61% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Bio-View Ltd Industry Peers by Asset Resilience Ratio
Compare Bio-View Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
TransMedics Group Inc
NASDAQ:TMDX |
Medical Devices | 0.00% |
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Shenzhen New Industries Biomedical
SHE:300832 |
Medical Devices | 9.95% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 34.37% |
|
Hangzhou AGS MedTech Co. Ltd. A
SHG:688581 |
Medical Devices | 18.80% |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580 |
Medical Devices | 10.74% |
|
Nanjing Medlander Medical Technology Co. Ltd. A
SHG:688273 |
Medical Devices | 34.29% |
Annual Asset Resilience Ratio for Bio-View Ltd (2023–2024)
The table below shows the annual Asset Resilience Ratio data for Bio-View Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 8.10% | ILA2.72 Million ≈ $7.30K |
ILA33.62 Million ≈ $90.14K |
+4.70pp |
| 2023-12-31 | 3.39% | ILA1.42 Million ≈ $3.82K |
ILA41.95 Million ≈ $112.48K |
-- |
About Bio-View Ltd
Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. The company's products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatic… Read more